The Molecular Immunology Laboratory works on the immunology of malaria, cancer and autoimmunity. In 2016, the laboratory discovered Programmed cell death1 Ligand 2 (PD-L2) was contrary to dogma, not a “brake” on the immune system, but actually an essential activator of immunity. The laboratory has since then used this finding to develop multiple immunotherapies and diagnostics for the treatment of cancer and autoimmunity. The first immunotherapy for cancer was licensed to Merck KGaA in 2020. However, the laboratory continues to also undertake basic immunological research to dissect the reason for loss of immunity during malaria and cancer or hyper-responses during autoimmunity.